MMR VACCINE SUSPENDED IN JAPAN
Following the withdrawal of the combined measles, mumps and rubella vaccines in the UK and Canada (Marketletters passim), the Japanese Health and Welfare Ministry has announced that all MMR vaccines currently on sale in Japan are to be withdrawn.
According to the Ministry, there seems to have been some variation in the incidence of associated axenic meningitis with the three vaccines withdrawn. However, the overall incidence was about one in 900. The ratio was derived from figures collected from 1988. A total of 1,667,103 vaccinations were recorded, with 1,683 of these children developing meningitis. The three companies that produce the vaccines are Kitasato Kenkyujo, Takeda and Handai Biseibutsubyo Kenkyukai.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze